Great Neck, NY (PRWEB) September 12, 2008
On August 14, 2008, Parker Waichman Alonso LLP filed suit on behalf of a Power Springs, Georgia man diagnosed with Nephrogenic Systemic Fibrosis (NSF) after receiving an injection of Omniscan, a gadolinium contrast dye manufactured by General Electric Company and its subsidiaries, GE Healthcare, Inc., GE Healthcare Medical Diagnostics, GE Medical Diagnostics, GE Healthcare AS and Novation LLC.
NSF is a condition that affects patients with pre-existing kidney disease who have been exposed to gadolinium contrast dyes such as Omniscan. NSF is a debilitating, often fatal disease that robs patients of their mobility. Symptoms of NSF include thickening and hardening of the skin, joint problems, muscle weakness and eye discoloration. The lawsuit was filed inwith the Multidistrict Legislation, the Northern District of Ohio (Docket Number: 1:08-gd-50266).
The patient, who had with pre-existing kidney disease, received an injection of gadolinium contrast dye on February 17, 2006 at Baptist Hospital in Miami. In February 2007, the plaintiff was diagnosed with NSF. He continues to suffer from the severe, debilitating and progressive fibrotic changes associated with NSF. This has permanently disabled, disfigured and severely impaired the plaintiff.
The lawsuit alleges that Omniscan is defective, and that the defendants failed to adequately test Omniscan and failed to warn patients about its potential to cause NSF.
The lawsuit further alleges that the chemical make-up of Omniscan makes it more likely that gadolinium will become free within the bodies of recipients, thereby making it more likely that kidney patients will develop NSF.
In September 2007, the Food & Drug Administration (FDA) asked the manufacturers of gadolinium contrast dyes to add a black box warning to the product labels about its association with NSF. The FDA also warned that patients with kidney disease should avoid gadolinium contrast agents.
NSF is a devastating condition characterized by high blood pressure, burning, itching, swelling and hardening of the skin. Other symptoms include eye discoloration, red or dark patches on the skin,; pain deep in the hip bones or ribs and muscle weakness. NSF can progress to the point of causing severe stiffness in joints, and it can lead to death.
There is currently no cure for NSF.
Numerous cases have been filed in more than a dozen different federal districts against gadolinium contrast dye manufacturers, including General Electric Company. On February 29, 2008 the U.S. Judicial Panel on Multidistrict Litigation designated the U.S. District Court for the Northern District of Ohio as the venue for the many lawsuits that have been filed, and those that will be filed in federal district court, against the makers of gadolinium contrast dyes. The panel indicated that the Northern District of Ohio provides a relatively central forum for the centralization of this nationwide litigation.
If you or a loved one has developed NSF after being administered a gadolinium contrast dye, please contact our office by visiting http://www.yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).
About Parker Waichman Alonso LLP
Parker Waichman Alonso LLP is a leading products liability and personal injury law firm that represents plaintiffs nationwide. The firm has offices in New York, New Jersey and Florida. Parker Waichman Alonso LLP has assisted thousands of clients in receiving fair compensation for injuries resulting from defective products, tainted foods, medications and medical devices.
Parker Waichman Alonso LLP
Fred R. Rosenthal, Managing Attorney
info @ yourlawyer.com